🔎 Trials Near Me

Utama › Leukemia › Iowa

Kajian klinikal Leukemia di Iowa

7 kajian untuk Leukemia sedang mencari peserta di lokasi di Iowa.

Bandar di Iowa

Teks kajian rasmi (Bahasa Inggeris)

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

  • University of Iowa Hospital, Iowa City
Mengambil pesertaFasa 1/2
30 Days · Semua jantina · Dikemas kini 16 Sep 2026 · NCT04065399

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

  • University of Iowa, Iowa City
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 20 Ogo 2026 · NCT07007312

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

  • University of Iowa Hospitals & Clinics, Iowa City
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 20 Ogo 2026 · NCT06001788

Integrated Cancer Repository for Cancer Research

  • Methodist Jennie Edmundson Hospital, Council Bluffs
  • Covenant Medical Center, Inc, Waterloo
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 19 hingga 110 · Semua jantina · Dikemas kini 29 Jun 2026 · NCT02012699

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

  • University of Iowa Hospitals & Clinics, Iowa City
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 13 Mac 2026 · NCT05735184

Activity Levels in Bone Marrow Transplant Patients

  • University of Iowa, Iowa City
Mengambil pesertaKajian pemerhatian
Umur 18 hingga 99 · Semua jantina · Dikemas kini 10 Nov 2025 · NCT04115241

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Iowa City
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 28 Okt 2025 · NCT03452774

Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.